演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

当院の婦人科癌に対して放射線治療後にベバシズマブを使用した13症例の検討

演題番号 : P94-6

[筆頭演者]
演者)古宇 家正:1 
[共同演者]
平田 英司:1、野坂 豪:1、山﨑 友美:1、占部 智:1、工藤 美樹:1

1:広島大学病院・産科婦人科

 

[Objectives] Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) receptor humanized monoclonal antibody that is an angiogenic inhibitor. It was approved for treating ovarian cancer in November 2013 and for treating progressive or recurrent cervical cancer in May 2016 in Japan. The number of cases with bevacizumab in progressive ovarian cancer has increased. Discontinuation period of bevacizumab is not established before and after the radiation therapy which is standard treatment of cervical cancer. Therefore, we examine cases using bevacizumab after radiation therapy for cervical cancer and ovarian cancer in our Hospital.
[Methods] We examined the side effects of bevacizumab among cases using bevacizumab after radiation therapy for cervical cancer or ovarian cancer from April 2014 to March 2018.
[Results] There were 8 cervical cancer cases and 5 ovarian cancer cases. Two and 11 cases were primary tumors and recurrences, respectively. We used bevacizumab more than 4 weeks after radiation therapy in all cases. Bevacizumab was discontinued in 5 cases because of side effects. Adverse events leading to termination of bevacizumab therapy consisted of the following: hypertension (1 case), thromboembolism (1 case), gastrointestinal ulcer (1 case), gastrointestinal perforation (1 case), bleeding that it was hard to control (1 case). One case that gastrointestinal perforation happened gave radiation therapy for a peritoneum dissemination lesion in recurrent ovarian cancer. We gave bevacizumab after six weeks from radiation therapy. It happened after four weeks after the 2 cycles dosage.
[Conclusions] We think that opportunities using bevacizumab after radiation therapy increase. Establishing bevacizumab patient selection criteria would allow for safe and effective use. Therefore, further examination of adverse events and accumulation of more cases are needed.

キーワード

臓器別:子宮

手法別:分子標的治療

前へ戻る